Replies to post #137388 on Biotech Values

[oc631]

That said, I did assume 189 was the leader.

It certainly is. Another question is whether a three drug GS-7977/Riba/? will be the first oral on the market. A lot depends on the results in GT1 treatment-naive patients. Another issue is are we looking at viral relapse or viral mutation in nulls and potentially naive patients?